Feichtenschlager et al. explore antisense oligonucleotides (ASOs) targeting NRAS-mRNA as a therapeutic approach for NRAS-mutant melanoma. Their findings demonstrate that the ASOs effectively eliminate NRAS-dependent melanoma cells, inhibit MAPK signaling, and synergize with kinase inhibitors, offering a promising strategy for clinical applications.
- Valentin Feichtenschlager
- Yixuan James Zheng
- Susana Ortiz-Urda
